Gilead stock falls as COVID-19 drug sales dwindle

Gilead Sciences Inc. reports a mixed quarter late Thursday, with sales below Wall Street expectations even as sales of its antiviral drug used to treat COVID-19 came in above forecast.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.